Quick Answer
TELA Bio, Inc. reported Total Revenue of $80.28 million for fiscal year 2025.
TELA Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $80.28M +15.8% |
$69.30M +18.6% |
$58.45M +41.1% |
$41.42M +40.6% |
$29.46M +61.8% |
$18.21M +17.9% |
| Revenue (ASC 606) | $80.28M +15.8% |
$69.30M +18.6% |
$58.45M +41.1% |
$41.42M +40.6% |
$29.46M +61.8% |
$18.21M +17.9% |
| Net Income | -$38.83M -2.6% |
-$37.84M +18.9% |
-$46.66M -5.3% |
-$44.30M -33.1% |
-$33.28M -15.6% |
-$28.79M -28.4% |
| Diluted EPS | -$0.83 +37.6% |
-$1.33 +34.8% |
-$2.04 +25.0% |
-$2.72 -18.3% |
-$2.30 -3.1% |
-$2.23 +87.0% |
| Total Assets | $81.42M -6.0% |
$86.57M +10.9% |
$78.05M +15.0% |
$67.86M +8.5% |
$62.54M -27.7% |
$86.46M +27.3% |
| Cash and Equivalents | $50.84M -3.5% |
$52.67M +12.7% |
$46.73M +11.2% |
$42.02M -4.4% |
$43.93M -40.9% |
$74.39M +64.2% |
| Long-Term Debt | $55.65M +35.3% |
$41.12M +1.5% |
$40.52M +1.5% |
$39.92M +26.8% |
$31.49M +2.2% |
$30.83M +1.9% |
| Stockholders Equity | $6.31M -77.8% |
$28.46M +50.7% |
$18.88M +32.0% |
$14.30M -28.8% |
$20.10M -59.0% |
$49.03M +58.3% |
| R&D Expense | $9.22M +4.6% |
$8.81M -8.4% |
$9.62M +7.6% |
$8.94M +32.5% |
$6.74M +58.5% |
$4.25M +2.5% |
| Operating Income | -$33.76M +1.1% |
-$34.12M +22.6% |
-$44.08M -13.0% |
-$39.01M -32.4% |
-$29.45M -16.5% |
-$25.27M -31.9% |
| Gross Profit | $54.34M +16.9% |
$46.49M +15.9% |
$40.11M +48.3% |
$27.04M +43.8% |
$18.81M +67.5% |
$11.23M +21.2% |
| Shares Outstanding | 44.54M +13.1% |
39.40M +60.8% |
24.49M +27.8% |
19.17M +31.9% |
14.53M +0.6% |
14.44M +26.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $20.69M | +9.1% | +2.4% |
| Revenue (ASC 606) | September 30, 2025 | $20.69M | +9.1% | +2.4% |
| Net Income | September 30, 2025 | -$8.60M | +17.1% | +13.3% |
| Diluted EPS | September 30, 2025 | -$0.19 | +54.8% | +13.6% |
| Total Assets | September 30, 2025 | $61.59M | +16.2% | -8.8% |
| Cash and Equivalents | September 30, 2025 | $29.71M | +71.7% | -15.0% |
| Long-Term Debt | September 30, 2025 | $41.49M | +1.3% | +9.0% |
| Stockholders Equity | September 30, 2025 | $1.56M | +124.8% | -83.0% |
| R&D Expense | September 30, 2025 | $2.35M | +13.5% | +6.6% |
| Operating Income | September 30, 2025 | -$7.55M | +19.3% | +16.8% |
| Gross Profit | September 30, 2025 | $13.97M | +8.6% | -1.0% |
| Shares Outstanding | September 30, 2025 | 40.34M | +63.2% | +1.9% |
- TELA Bio, Inc. reported Total Revenue of $80.28 million for fiscal year 2025.
- TELA Bio, Inc. showed an increase of +15.8% in Total Revenue compared to the prior fiscal year.
- TELA Bio, Inc. reported Revenue (ASC 606) of $80.28 million for fiscal year 2025.
- TELA Bio, Inc. showed an increase of +15.8% in Revenue (ASC 606) compared to the prior fiscal year.
- TELA Bio, Inc. reported Net Income of -$38.83 million for fiscal year 2025.
- TELA Bio, Inc. showed a decrease of -2.6% in Net Income compared to the prior fiscal year.
- TELA Bio, Inc. reported Diluted EPS of $0.83 per share (loss) for fiscal year 2025.
- TELA Bio, Inc. showed an increase of +37.6% in Diluted EPS compared to the prior fiscal year.
- TELA Bio, Inc. reported Total Assets of $81.42 million for fiscal year 2025.
- TELA Bio, Inc. showed a decrease of -6.0% in Total Assets compared to the prior fiscal year.
- TELA Bio, Inc. reported Cash and Equivalents of $50.84 million for fiscal year 2025.
- TELA Bio, Inc. showed a decrease of -3.5% in Cash and Equivalents compared to the prior fiscal year.
- TELA Bio, Inc. reported Long-Term Debt of $55.65 million for fiscal year 2025.
- TELA Bio, Inc. showed an increase of +35.3% in Long-Term Debt compared to the prior fiscal year.
- TELA Bio, Inc. reported Stockholders Equity of $6.31 million for fiscal year 2025.
- TELA Bio, Inc. showed a decrease of -77.8% in Stockholders Equity compared to the prior fiscal year.
- TELA Bio, Inc. reported R&D Expense of $9.22 million for fiscal year 2025.
- TELA Bio, Inc. showed an increase of +4.6% in R&D Expense compared to the prior fiscal year.
- TELA Bio, Inc. reported Operating Income of -$33.76 million for fiscal year 2025.
- TELA Bio, Inc. showed an increase of +1.1% in Operating Income compared to the prior fiscal year.
- TELA Bio, Inc. reported Gross Profit of $54.34 million for fiscal year 2025.
- TELA Bio, Inc. showed an increase of +16.9% in Gross Profit compared to the prior fiscal year.
- TELA Bio, Inc. reported Shares Outstanding of 44.54 million shares for fiscal year 2025.
- TELA Bio, Inc. showed an increase of +13.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: